Abstract
Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have